Efficacy and safety of tirzepatide for weight reduction in Chinese adults with overweight/obesity: A randomized clinical trial

VernacularTitle:替尔泊肽在中国超重/肥胖成人中的疗效和安全性：一项随机对照试验
Author: Lin ZHAO ¹ ; Zhifeng CHENG ; Yibing LU ; Ming LIU ; Hong CHEN ; Min ZHANG ; Rui WANG ; Yuan YUAN ; Xiaoying LI
Author Information

1. 复旦大学附属中山医院内分泌科，上海　200032
Keywords: Tirzepatide; Glucagon-like peptide-1/Glucose-dependent insulintropic polypeptide receptor agonist; Obesity
From: Chinese Journal of Endocrinology and Metabolism 2024;40(8):637-640
CountryChina
Language:Chinese
Abstract: This article introduces a recent paper published in JAMA titled " Tirzepatide for weight reduction in Chinese adults with obesity: The SURMOUNT-CN randomised clinical trial". The paper details the design, results, and implications of a randomized controlled clinical study of the efficacy and safety of tirzepatide in overweight/obese adults in China(SURMOUNT-CN). This study represents the first Chinese evidence supporting tirzepatide for the treatment of obesity, offering a potent therapeutic option for the prevention and treatment of obesity and weight-related comorbidity.